Join Us for Our Pancreatic Cancer Cell Line Launch
A New Generation of Cell Lines For Pancreatic Cancer: Paving The Way For Better Research
Cellaria Inc, a scientific innovator with breakthrough tools 7 reagents for cancer research, is launching the next generation of pancreatic cancer cell lines. These cell lines boost the value of in vitro methods throughout drug discovery and development. Difficult to detect and with a poor survival rate, pancreatic cancer is responsible for more than 400,000 deaths per year, globally, and a primary target for researchers.
Challenges with Existing Cancer Cell Lines
- Results from established cell lines and animal models do not translate into actionable clinical data
- There is a lack of reproducibility in the research produced with the same cell lines from lab to lab
- Cell lines represent one form of a disease
- Cell lines only allow scientists to form assumptions of how a drug will behave based on risk/probability prediction of how will perform in general patient population
The challenges that come from the existing system result in billions of dollars of yearly research. While the research is really important, the pre-clinical cell research does not represent the way a potential treatment will behave in a person.
Cellaria's pancreatic cell models change that.
Meet Cellaria's New Generation of Pancreatic Cell Lines
Join us, September 29th, at the official product launch of Stew, Chocolate, and Basket - 3 new patient-specific cancer cell models (research-use only). Here's a taste of how they pave the way for better, and more relevant, research.
- Patient Specificity - allows researchers to evaluate efficacy of pre-clinical research against a range of patient subpopulations.
- Much More Reliable & Stable - more stable than traditional cell lines, the new pancreatic research cell lines maintain biomarker expression and cell heterogeneity for longer
- Rigorously Authenticated - Each line comes with a Certificate of Analysis (COA) that describes growth characteristics, protocols for preserving biomarker expression and response to a minimum of three established drug therapies.